XOMA is a biotechnology company specializing in the discovery, development, and manufacturing of innovative antibody therapeutics. The company’s monoclonal antibody technologies have aided in developing marketed biologics totaling over $1 billion in annual sales – for which XOMA has received substantial royalties. The company’s lead drug candidate is gevokizumab (XOMA 052), which is a humanized antibody that modulates the inflammatory cytokine interleukin-1 beta. This year, XOMA is expected to initiate global phase 3 clinical development of gevokizumab. For more information, visit the company’s Web site at www.xoma.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: